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=======

In this letter, we wish to correct errors in the previously published article \[[@CR1]\]. Although the errors do not change the main results and conclusions described in the abstract of the original article, we believe providing the correct information is important. The major correction is about the genotype distribution of HEV in Africa. In the original article, we indicated that genotype 3 is rare and less commonly found than genotype 2 while genotype 1 is the most prevalent. The correct information is, however, that genotypes 2 and 3 were identified at a similar frequency while genotype 1 was the most prevalent. This error arose because the genotypes of HEV identified in seven Nigerian adults \[89\] were mistaken to be 2, when their actual genotype was 3. In what follows, we revised the relevant section named "Genotype prevalence" on page 5 of the original article and the relevant table and figure (i.e., Table [5](#Tab3){ref-type="table"} and Fig. [2](#Fig1){ref-type="fig"}).Table 1Seroprevalence of anti-HEV antibodies in Africa. Seroprevalence varies by country and by subpopulation and studies were done under different conditions (e.g., sample size, demographics, and different diagnostic methods). Age of the sample is provided as mean (range or ± standard deviation, if available)Country% sero-prevalenceSample demographicsSample sizeYear of samplingDiagnostic methodsSourceBurkina Faso19.1Blood donors1782010-12IgG\[29\]11.6Pregnant women1892010-12IgG\[29\]Burundi14.0Adults without chronic liver disease, 44.7 yrs old (±13.5)1291986Total Ig\[30\]Cameroon14.2HIV-infected adults, 38.1 yrs old (±11.3)and2892009-10IgG\[32\]2.0HIV-infected children, 8.3 yrs old (±7.5)1002009-10IgG\[32\]CAR^a^24.2Patients attending the center for sexually transmitted diseases1571995^b^Total Ig\[33\]Djibouti13.0Male peacekeepers in Haiti, 31.2 yrs old1121998^b^Total Ig\[42\]Egypt84.3Pregnant women, 24 yrs old (16-48)2,4281997-2003Total Ig\[55\]80.1Patients with chronic liver disease, 48 yrs old (23-62)5182000-2IgG\[57\]67.6Residents of two rural villages, 24.5 and 26.5 yrs, respectively10,1561997Total Ig\[54\]58.6Asymptomatic pregnant women, \~33 yrs old1162009IgG\[58\]56.4Residents of a semi-urban village, 1-67 yrs old1401993Total Ig\[51\]54.1Four waste water treatment plant male workers, 20-60 yrs old2051998-9IgG\[116\]51.2Waste water treatment plant workers, 47.1 yrs old432011^b^Total Ig\[60\]50.6Waste water treatment plant workers, 20-60 yrs old2332000^b^Total Ig\[61\]45.3Blood donors, 18-45 yrs old951998^b^IgG\[52\]39.6Haemodialysis patients, 8-20 yrs old961998^b^IgG\[52\]38.9Healthy females, 21.8 yrs old (16-25)951995IgG\[50\]17.2Residents of a hamlet, 20.9 yrs old (\<1-95)12591992IgG\[49\]0.0Healthy controls, 20--60 yrs old961998-9IgG\[116\]Gabon14.2Pregnant women, 24.6 yrs old (14-44)8402005, 2007IgG\[73\]0.0Villagers, 29 yrs old (2-80)351991-2Total Ig\[72\]Ghana45.3Adult HIV patients, 40 yrs old (±9.6)4022008-10IgG\[32\]38.1Pig handlers, 36.5 yrs old (12-65)1052009^b^Total Ig\[77\]34.8Pig handlers, 32.9 yrs old (15-70)3532008Total Ig\[75\]28.7Pregnant women, 28.9 yrs old (13-42)1572008Total Ig\[78\]4.6Blood donors2392012^b^IgG\[76\]4.46-18 yr olds8031993Total Ig\[74\]Madagascar14.1Slaughterhouse workers4272008-9Total Ig\[81\]Morocco8.5Blood donors2002000-1IgG\[85\]2.2men (*n* = 232) and women (*n* = 259), 27.7 yrs old (±5.9)4911995^b^IgG\[84\]Nigeria94.0Control healthy adults (*n* = 44)442008-9Total Ig\[90\]43.0Health care workers882008-9Total Ig\[90\]13.4Healthy and sick people, 29.8 yrs old (3-72)1862007Total Ig\[91\]Sierra Leone7.6Primary school children, 6-12 yrs old661998^b^IgG\[139\]South Africa10.7Urban (*n* = 407) and rural (*n* = 360) blacks, 42 yrs old (18-85)7671996^b^Total Ig\[98,117\]2.6Medical students2271992Total Ig\[97\]1.8Canoeists who have been regularly exposed to waste water5551992Total Ig\[97\]Tanzania6.6Women, 32.1 yrs old (15-45)2121996Total Ig\[114\]0.2Healthy adults, 30.3 yrs old4031992Total Ig\[112\]0.0Women1801995Total Ig\[113\]Tunisia46.0Healthy persons, \> 60 yrs old1001991IgG\[106\]29.5Children with chronic haematological diseases341996IgG\[106\]28.9Polytransfused patients; adults (*n* = 59, 34.8 yrs old \[20-61\]) and children (*n* = 48, 7.3 yrs old \[1-15\])1072008-9IgG\[107\]22.0Healthy blood donors, \< 40 yrs old1001996IgG\[106\]12.1Pregnant women, 30.1 yrs old (17-52)4042008-9IgG\[108\]10.0Healthy controls; blood donors (*n* = 100, 31.3 yrs old \[20--58\])\
and children, (*n* = 60, 7.9 yrs old \[1--15\])1602008-9IgG\[107\]5.4Blood donors, 32.6 yrs old (± 8.6)6872007-8Total Ig\[109\]4.3Healthy persons, 20.7 yrs old (16-25)1,5052008^b^IgG\[110\]Zambia40.6^c^Urban adults, 18--64 yrs old1061999IgG\[115\]16.0Urban children, 1--15 yrs old1942011IgG\[115\]^a^CAR; Central African Republic^b^The year of the publication^c^The original study reports 42%, but the actual figures indicate that 43 out of 106 specimens are positive; 43/106 = 0.4056 Table 2Sporadic cases caused by hepatitis E virus in Africa. Proportion of sporadic hepatitis cases attributable to HEV varies by country and by subpopulation and studies were done under different conditions (e.g., sample size, demographics, and different diagnostic methods). Age of the sample is provided as mean (range or ± standard deviation, if available)Country% sero-positivityCase demographicsNo. of casesYear of samplingDiagnostic methodsSourceChad48.8Acute or fulminant hepatitis patients, 4-64 yrs old411993IgM\[36\]20.0^a^Sporadic cases171994RT-PCR^b^\[27\]Djibouti58.5Acute hepatitis patients, 21.8 yrs old (2-65)651992-3IgM\[41\]Egypt24.2Jaundiced patients, 1-73 yrs old2021993IgM\[46\]22.2Jaundiced children, 5 yrs old (1-11)2611990IgM\[70\]21.7Acute hepatitis patients, 26.6 yrs old (18-60)1431993-4IgM\[71\]20.2Acute viral hepatitis patients, 8 yrs old2872006-8IgM\[62\]17.9Acute hepatitis patients, 15.7 (± 14.9) yrs old2352007-8IgM or \> = 3-fold rise in IgG\[69\]17.2Children with elevated level (two-fold or more) of AST and ALT642006^d^IgM\[47\]15.7Acute hepatitis patients, 15.9 yrs old (1-65)2352007-8IgM\[63\]15.1Children with acute jaundice, 6.4 yrs old (1-13)731987-8IgM\[45\]12.5Patients with acute hepatitis, 20.2 yrs old (4-65)2002001-2IgM\[64\]6.0Children with minor hepatic ailments, 6 mo-10 yrs1002004-5IgM\[65\]5.0Patients with acute on chronic liver failure, 46.4 yrs old1002009-10IgM\[66\]2.1Acute viral hepatitis patients, 25 yrs old (2-77)472002-5IgM\[76\]2.0Hepatitis patients, 5.4 yrs old (1.5-15)502007RT-PCR\[48\]Ethiopia45.6Acute viral hepatitis patients with NANB791988-91FABA^d^\[43\]31.8Non-pregnant women with acute viral hepatitis, 30 yrs old221988-91FABA\[6\]67.9Pregnant women with acute viral hepatitis, 26 yrs old281988-91FABA\[6\]Mayotte100.0Patients with acute jaundice, 46 yrs old12009IgM\[82\]Nigeria70.0Male patients with acute hepatitis, 25-33 yrs old101997-8RT-PCR\[89\]Senegal20.0Patients with jaundice301992^c^IgM\[93\]10.2Patients with viral hepatitis491993^c^IgM\[92\]Somalia61.1Native Somalis and displaced Ethiopian patients with acute hepatitis, 7-90 yrs old361992-3IgM\[96\]Sudan5.4Patients with fulminant hepatic failure, 38 yrs old (19-75)372003-4IgM\[103\]59.0Children with acute clinical jaundice, ≤14 yrs old391987-8IgM\[118\]^a^20% was extrapolated from the results of RT-PCR of 5 samples out of total 17 cases^b^Reverse transcription polymerase chain reaction^c^The year of the publication^d^FABA; fluorescent antibody blocking assay, which is claimed to detect acute infection, not but past infection Table 5Genotype distribution from African HEVsGenotypeCountryYear of samplingSampleRNA region testedSource1CAR^a^2002One fecal sample from an outbreakNA^b^\[34\]Chad1984A patient with hepatitis EComplete genome\[28\]2004Five isolates from an outbreakORF^c^2 (363 nt^d^)\[35\]Egypt1993Acute hepatitis patientsORF1 (location: 55-320)\[46\]2006-8Acute hepatitis patientsORF1\[62\]2012^e^Sixteen isolates from acute hepatitis patientsORF2 (189 nt)\[124\]Namibia1983Nine isolates from an outbreak in KavangoORF2 (296 nt), 3 (188 nt)\[88\]Sudan2004Twenty three isolates from an outbreakORF2 (363 nt)\[35\]Uganda2007Internally displaced persons campNA\[123\]2008Twenty four isolates from an outbreakNA\[119\]2CAR2002Three fecal samples from an outbreakNA\[34\]Chad2004Four isolates from an outbreakORF2 (363 nt)\[35\]Namibia1995Four isolates from NANB outbreak in RunduORF2 (451 nt near 3\'-end)\[87\]3Nigeria2000^e^Ten adult acute hepatitis patientsORF1, 2 (3\'-end)\[89\]Egypt2007One 9 year-old acute hepatitis patientORF1, 2, 2/3\[48\]Mayotte2009One French acute hepatitis patient (46 yr old)ORF2 (288 nt)\[82\]Madagascar2009Slaughter house workersORF2,3 (1000 nt)\[81\]^a^CAR; Central African Republic^b^NA; not available^c^ORF; open reading frame^d^nt; nucleotides^e^Publication year Fig. 2Map of Africa. Colored areas represent countries where HEV is endemic at least for some subpopulations or sporadic HEV cases or outbreaks have been detected. Circles indicate HEV outbreaks with centers and areas indicating the location and outbreak size, respectively. Different colors represent different genotypes. White areas indicate countries where no data is available

Genotype prevalence {#Sec2}
===================

Data on the genotypes of circulating HEV's are available for 9 countries (16 studies). Table [5](#Tab3){ref-type="table"} presents a summary sorted by genotype and also provides characteristics of the sample, genomic regions tested. Genotype 1 seems to be most prevalent as it was found in Central African Republic \[34\], Sudan \[35\], Chad \[28, 35\], Egypt \[46, 62, 124\], and Namibia \[88\] followed by genotype 2 and 3, of which both were observed at a similar frequency. Genotype 2 was found in Central African Republic \[34\], Chad \[35\], and Namibia \[87\]. Genotype 3 was observed in one Egyptian child \[48\], one acute hepatitis patient in Mayotte (originally from France) \[82\], seven Nigerian adults with acute hepatitis E \[89\], and slaughter house workers in Madagascar \[81\]. Genotype prevalence can differ in neighboring countries as was demonstrated by one study in Sudan and Chad where genotype 1 was more common in Sudan and genotype 2 was more common in Chad \[35\]. Figure [2](#Fig1){ref-type="fig"} shows a map of Africa where countries in which HEV infections were observed are differently colored according to HEV genotype.

We corrected additional minor errors in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} although these corrections do not cause any changes in the main text. We have made three revisions to Table [1](#Tab1){ref-type="table"} of the original article:The seroprevalence of a Zambian population were 42% and 16%, which should be 40.6% and 16.0%, respectively \[115\]The sample size, (*n* = 402), in the description of the study conducted in Ghana (the first row of Ghana) was removed to avoid duplicationThe study of HEV in Sierra Leone was mistaken to be omitted in the original article with no reference included. It is now included in the revised Table [1](#Tab1){ref-type="table"} with the full reference \[139\]

The order of table cells was rearranged for Egyptian data by descending seroprevalence to make it consistent across countries. For Table [2](#Tab2){ref-type="table"}, some of decimal points appear as middle dots in the original article, which were revised to be the same as other decimal points (i.e., periods) in the revised Table [2](#Tab2){ref-type="table"}.
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The online version of the original article can be found under doi:10.1186/1471-2334-14-308.
